Latest Period
Q1 2026
Security Snapshot
Centessa Pharmaceuticals plc - Ordinary Shares, nominal value GBP 0.002 per share (CNTA) Institutional Ownership
CUSIP: 152309100
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
160
Shares (Excl. Options)
148,632,709
Price
$39.72
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, nominal value GBP 0.002 per share
- Symbol
- CNTA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 148,632,709
- Total 13F value
- $5,896,478,651
- Portfolio coverage rank
- 0.01%
- Share change
- +4,874,750
- Value change
- +$329,840,050
- Number of holders
- 160
- Shares outstanding
- 154,150,943
- SEC-reported price per share
- $39.58
- Insider filing price
- $39.58
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CNTA - Centessa Pharmaceuticals plc - Ordinary Shares, nominal value GBP 0.002 per share is tracked under CUSIP 152309100.
- 160 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 147 to 160 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $3,595,359,236 to $5,896,478,651.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 160 institutions filings for Q1 2026.
Security key
152309100
Latest holder period
Q1 2026
13F holders
160
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
CNTA full holder history
Centessa Pharmaceuticals plc SEC filings
Centessa Pharmaceuticals plc company facts
Centessa Pharmaceuticals plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 152309100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
CNTA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 7.4% | -26% | $452,303,104 | -$123,660,207 | 11,430,455 | -21% | Avoro Capital Advisors LLC | 31 Mar 2026 |
| Adage Capital Management, L.P. | 5.8% | -24% | $353,162,646 | -$43,922,304 | 8,925,010 | -11% | Adage Capital Management, L.P. | 31 Mar 2026 |
| Pentwater Capital Management LP | 5.3% | $323,286,900 | 8,170,000 | Pentwater Capital Management LP | 31 Mar 2026 | |||
| General Atlantic Cooperatief U.A. | 5% | -23% | $180,192,368 | -$56,624,900 | 7,366,818 | -24% | General Atlantic Cooperatief U.A. | 25 Nov 2025 |
| FMR LLC | 7.5% | -39% | $268,405,170 | -$166,856,639 | 6,783,047 | -38% | FMR LLC | 31 Mar 2026 |
As of 31 Mar 2026, 160 institutional investors reported holding 148,632,709 shares of Centessa Pharmaceuticals plc - Ordinary Shares, nominal value GBP 0.002 per share (CNTA). This represents 96% of the company’s total 154,150,943 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
80%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 13% | 19,963,157 | 0% | 81% | $792,936,596 |
| Avoro Capital Advisors LLC | 7.4% | 11,430,455 | -21% | 4.5% | $454,017,673 |
| Index Venture Life Associates VI Ltd | 6.5% | 9,961,789 | 0% | 100% | $395,682,259 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.8% | 8,925,010 | -21% | 0.55% | $354,501,397 |
| Pentwater Capital Management LP | 5.3% | 8,170,000 | 2.3% | $324,512,400 | |
| FMR LLC | 4.4% | 6,852,047 | -24% | 0.01% | $272,163,307 |
| EcoR1 Capital, LLC | 3.9% | 6,000,000 | +93% | 10% | $238,320,000 |
| PERCEPTIVE ADVISORS LLC | 3.4% | 5,258,903 | +80% | 4.1% | $208,883,627 |
| Capital World Investors | 3.1% | 4,832,548 | +317% | 0.03% | $191,948,807 |
| FARALLON CAPITAL MANAGEMENT LLC | 3.1% | 4,809,000 | -11% | 1.2% | $191,013,480 |
| TCG Crossover Management, LLC | 2.8% | 4,286,480 | 0% | 4.9% | $170,258,986 |
| MORGAN STANLEY | 2.8% | 4,268,353 | +285% | 0.01% | $169,538,989 |
| Paradigm Biocapital Advisors LP | 2.3% | 3,574,048 | 2.9% | $141,961,187 | |
| JANUS HENDERSON GROUP PLC | 2.3% | 3,492,977 | -15% | 0.07% | $138,741,046 |
| Deep Track Capital, LP | 2% | 3,158,041 | +58% | 2.6% | $125,437,389 |
| Logos Global Management LP | 1.4% | 2,125,000 | +962% | 4.3% | $84,405,000 |
| RTW INVESTMENTS, LP | 1.3% | 2,054,175 | +15% | 0.81% | $81,591,831 |
| FEDERATED HERMES, INC. | 1.3% | 2,049,439 | -12% | 0.13% | $81,403,717 |
| BRAIDWELL LP | 1.3% | 1,986,768 | -9.2% | 2.6% | $78,914,425 |
| BANK OF AMERICA CORP /DE/ | 1.3% | 1,932,406 | +104% | 0.01% | $76,755,166 |
| MAVERICK CAPITAL LTD | 1.2% | 1,854,488 | +13% | 0.86% | $73,660,263 |
| First Light Asset Management, LLC | 1% | 1,560,991 | -32% | 5.6% | $62,002,563 |
| Affinity Asset Advisors, LLC | 0.91% | 1,400,000 | +133% | 3.3% | $55,608,000 |
| Foresite Capital Management VI LLC | 0.88% | 1,364,019 | 0% | 12% | $54,178,835 |
| GENERAL ATLANTIC, L.P. | 0.88% | 1,354,830 | -78% | 2.5% | $53,813,848 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q1 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 148,632,709 | $5,896,478,651 | +$329,840,050 | $39.72 | 160 |
| 2025 Q4 | 143,761,351 | $3,595,359,236 | +$388,868,676 | $25.01 | 147 |
| 2025 Q3 | 128,332,503 | $3,111,987,564 | +$147,803,679 | $24.25 | 124 |
| 2025 Q2 | 123,569,478 | $1,623,678,828 | -$30,690,539 | $13.14 | 117 |
| 2025 Q1 | 124,913,742 | $1,797,461,231 | -$6,439,160 | $14.38 | 130 |
| 2024 Q4 | 124,413,136 | $2,083,915,345 | +$72,898,202 | $16.75 | 114 |
| 2024 Q3 | 108,571,980 | $1,737,489,847 | +$315,516,266 | $15.99 | 101 |
| 2024 Q2 | 86,506,981 | $781,158,600 | +$108,671,569 | $9.03 | 79 |
| 2024 Q1 | 74,395,267 | $840,663,455 | +$66,659,727 | $11.30 | 69 |
| 2023 Q4 | 71,279,084 | $567,382,245 | +$15,317,885 | $7.96 | 56 |
| 2023 Q3 | 72,578,425 | $469,582,127 | +$14,480,766 | $6.47 | 46 |
| 2023 Q2 | 70,339,619 | $435,403,089 | +$25,413,534 | $6.19 | 43 |
| 2023 Q1 | 66,895,058 | $257,540,618 | +$13,125,714 | $3.85 | 42 |
| 2022 Q4 | 62,684,642 | $194,353,719 | +$5,918,047 | $3.10 | 41 |
| 2022 Q3 | 71,808,783 | $288,649,039 | -$842,289 | $4.02 | 41 |
| 2022 Q2 | 71,775,040 | $349,577,531 | -$37,633,222 | $4.87 | 40 |
| 2022 Q1 | 74,581,035 | $669,057,512 | +$23,146,015 | $8.97 | 40 |
| 2021 Q4 | 71,873,880 | $807,766,000 | +$18,577,946 | $11.26 | 46 |
| 2021 Q3 | 52,983,439 | $881,813,000 | +$147,088,157 | $16.70 | 38 |
| 2021 Q2 | 47,409,892 | $1,045,414,000 | +$1,045,413,999 | $22.21 | 49 |